13087 Results

People

  1. Giralt
    Giralt
  2. Perales
    Perales
  3. Levine
    Levine
  4. Zelenetz
    Zelenetz
  5. Horwitz
    Horwitz
  6. Abdel-Wahab
    Abdel-Wahab
  7. Scheinberg
    Scheinberg
  8. Jakubowski
    Jakubowski
  9. Landau
    Landau
  10. Shah
    Shah

Groups

  1. Hematologic Malignancies, Division of (13087)
  2. Department of Medicine (13003)
  3. Center for Hematologic Malignancies (10394)
  4. GSK Faculty (4421)
  5. Adult Leukemia (3582)
  6. Bone Marrow Transplant (2776)
  7. Lymphoma (2639)
  8. Sloan Kettering Institute Faculty (2602)
  9. Executive Committee, Center for Hematologic Malignancies (2358)
  10. Survivorship Research (2328)
  1. "Hematologic Malignancies, Division of"
Formats
  1. Meeting Abstract (6210)
  2. Journal Article (5696)
  3. Review (405)
  4. Book Section (186)
  5. Editorial (186)
  6. Research Letter (169)
  7. Guidelines (86)
  8. Conference Paper (65)
  9. Correspondence (58)
  10. Miscellaneous (17)
  11. Book Whole (9)
Groups
  1. Hematologic Malignancies, Division of (13087)
  2. Department of Medicine (13003)
  3. Center for Hematologic Malignancies (10394)
  4. GSK Faculty (4421)
  5. Adult Leukemia (3582)
  6. Bone Marrow Transplant (2776)

More Groups

People
  1. Sergio Giralt (1050)
  2. Miguel-Angel Perales (913)
  3. Ross Levine (774)
  4. Andrew Zelenetz (767)
  5. Martin Tallman (649)
  6. Steven Horwitz (645)

More People

Years
  1. 2025 (203)
  2. 2024 (670)
  3. 2023 (1038)
  4. 2022 (964)
  5. 2021 (875)
  6. 2020 (936)

More Years

Publications
  1. Blood (3371)
  2. Journal of Clinical Oncology (1214)
  3. Biology of Blood and Marrow Transplantation (596)
  4. Clinical Lymphoma, Myeloma and Leukemia (328)
  5. Haematologica (289)
  6. Bone Marrow Transplantation (238)

More Publications

Publishers
  1. American Society of Hematology (3638)
  2. Elsevier Inc. (1609)
  3. American Society of Clinical Oncology (1266)
  4. Nature Publishing Group (994)
  5. American Association for Cancer Research (637)
  6. Wiley Blackwell (430)

More Publishers

Results (13087)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Protein profiles predict treatment responses to the PI3K inhibitor umbralisib in patients with chronic lymphocytic leukemia
    Journal Article

    Yin, Y.; Xu, H.; He, L.; Brown, J. R.; Mato, A. R.; Aittokallio, T.; Skånland, S. S.
    Clinical Cancer Research (2025)

    Fulltext@MSK | Save
  • Safety and tolerability of lete-cel in NSCLC—Reply
    Correspondence

    Altan, M.; Lopes, G.; Hiltermann, T. J. N.; Govindan, R.; Villaruz, L. C.; Calvo, E.; Edelman, M. J.; Furqan, M.; Neal, J.; Felip, E.; more...
    Clinical Cancer Research (2025)

    Fulltext@MSK | Save
  • Clinical implications of the cancer genome atlas molecular classification system in esophagogastric cancer
    Journal Article

    Walch, H. S.; Borpatragohain, R.; Jee, J.; Chatila, W.; Fong, C.; Maron, S. B.; Ku, G. Y.; Ilson, D. H.; Janjigian, Y. Y.; Wu, A. J.; more...
    Clinical Cancer Research (2025)

    Fulltext@MSK | Save
  • A phase I dose-escalation study of the HIF-2 alpha inhibitor DFF332 in patients with advanced clear-cell renal cell carcinoma
    Journal Article

    Pal, S. K.; Bernard-Tessier, A.; Grell, P.; Gao, X.; Kotecha, R. R.; Picus, J.; de Braud, F.; Takahashi, S.; Wong, A.; Suárez, C.; more...
    Clinical Cancer Research (2025)

    Fulltext@MSK | Save
  • Accurate prediction of absolute prokaryotic abundance from DNA concentration
    Journal Article

    Wirbel, J.; Andermann, T. M.; Brooks, E. F.; Evans, L.; Groth, A.; Dvorak, M.; Chakraborty, M.; Palushaj, B.; Reynolds, G. Z. M.; Porter, I. E.; more...
    Cell Reports Methods (2025)

    Fulltext@MSK | Save
  • Pharmacokinetic profile of novel reduced-dose Danziten(TM) (nilotinib tablets) versus Tasigna® (nilotinib capsules): In vivo bioequivalence and population pharmacokinetic analysis
    Journal Article

    Mauro, M.; Radich, J.; Jain, P.; Sequeira, D.; Bellanti, F.; Douer, D.
    Cancer Chemotherapy and Pharmacology (2025)

    Fulltext@MSK | Save
  • Assessing AML-based risk criteria in patients with accelerated/blastphase MPN treated with less-intensive therapy
    Research Letter

    Shaw, R.; Yoon, J. J.; Johnston, H.; Davidson, M. B.; Siddon, A. J.; Shallis, R. M.; Chen, E. C.; Burkart, M.; Oh, T. S.; Iyer, S. G.; more...
    Blood Advances (2025)

    Fulltext@MSK | Save
  • Dual targeting of EZH2 and EZH1 drives exit of leukemia stem cells from quiescence and potentiates chemotherapy in acute myeloid leukemia
    Research Letter

    Akiyama, H.; Nishida, Y.; Chang, K. H.; Bedoy, A. D.; Muftuoglu, M.; Ma, W.; Basyal, M.; Hirschi, Z.; Honma, D.; Tsutsumi, S.; more...
    Blood Cancer Journal (2025)

    Fulltext@MSK | Save
  • Outcomes with first-line ipilimumab and nivolumab for patients with metastatic renal cell carcinoma by number of doses
    Meeting Abstract

    Doshi, S. D.; Sanmiguel, A. L.; Knezevic, A.; Kotecha, R. R.; Shah, N. J.; Carlo, M.; Feldman, D. R.; Motzer, R. J.; Voss, M. H.
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Characterizing the immune effects of enfortumab vedotin (EV) on peripheral blood mononuclear cells (PBMCs) in metastatic urothelial cancer patients (mUC)
    Meeting Abstract

    Gupta, A.; Sevilla, C.; Pihlstrom, N. L.; Liang, S.; Regazzi, A. M.; McCoy, A. S.; Maher, C. A.; Wong, P.; Ahmed, F.; Funt, S. A.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save